RESUMEN
Accurate assessment of blood pressure is fundamental to the provision of safe obstetrical care. It is simple, cost effective, and life-saving. Treatments for preeclampsia, including antihypertensive drugs, magnesium sulfate, and delivery, are available in many settings. However, the instigation of appropriate treatment relies on prompt and accurate recognition of hypertension. There are a number of different techniques for blood pressure assessment, including the auscultatory method, automated oscillometric devices, home blood pressure monitoring, ambulatory monitoring, and invasive monitoring. The auscultatory method with a mercury sphygmomanometer and the use of Korotkoff sounds was previously recommended as the gold standard technique. Mercury sphygmomanometers have been withdrawn owing to safety concerns and replaced with aneroid devices, but these are particularly prone to calibration errors and regular calibration is imperative to ensure accuracy. Automated oscillometric devices are straightforward to use, but the physiological changes in healthy pregnancy and pathologic changes in preeclampsia may affect the accuracy of a device and monitors must be validated. Validation protocols classify pregnant women as a "special population," and protocols must include 15 women in each category of normotensive pregnancy, hypertensive pregnancy, and preeclampsia. In addition to a scarcity of devices validated for pregnancy and preeclampsia, other pitfalls that cause inaccuracy include the lack of training and poor technique. Blood pressure assessment can be affected by maternal position, inappropriate cuff size, conversation, caffeine, smoking, and irregular heart rate. For home blood pressure monitoring, appropriate instruction should be given on how to use the device. The classification of hypertension and hypertensive disorders of pregnancy has recently been revised. These are classified as preeclampsia, transient gestational hypertension, gestational hypertension, white-coat hypertension, masked hypertension, chronic hypertension, and chronic hypertension with superimposed preeclampsia. Blood pressure varies across gestation and by ethnicity, but gestation-specific thresholds have not been adopted. Hypertension is defined as a sustained systolic blood pressure of ≥140 mm Hg or a sustained diastolic blood pressure of ≥90 mm Hg. In some guidelines, the threshold of diagnosis depends on the setting in which blood pressure measurement is taken, with a threshold of 140/90 mm Hg in a healthcare setting, 135/85 mm Hg at home, or a 24-hour average blood pressure on ambulatory monitoring of >126/76 mm Hg. Some differences exist among organizations with respect to the criteria for the diagnosis of preeclampsia and the correct threshold for intervention and target blood pressure once treatment has been instigated. Home blood pressure monitoring is currently a focus for research. Novel technologies, including early warning devices (such as the CRADLE Vital Signs Alert device) and telemedicine, may provide strategies that prompt earlier recognition of abnormal blood pressure and therefore improve management. The purpose of this review is to provide an update on methods to assess blood pressure in pregnancy and appropriate technique to optimize accuracy. The importance of accurate blood pressure assessment is emphasized with a discussion of preeclampsia prediction and treatment of severe hypertension. Classification of hypertensive disorders and thresholds for treatment will be discussed, including novel developments in the field.
Asunto(s)
Determinación de la Presión Sanguínea/métodos , Hipertensión Inducida en el Embarazo/diagnóstico , Determinación de la Presión Sanguínea/instrumentación , Femenino , Humanos , Hipertensión Inducida en el Embarazo/clasificación , Atención Posnatal , Embarazo , Choque/diagnósticoRESUMEN
The centuries-old approach to the prevention of eclampsia and its associated maternal morbidity and mortality is based on the recognition of the presence of premonitory signs and symptoms such as hypertension and proteinuria. The spectrum of preceding signs and symptoms came to be known as preeclampsia, which is debatably considered to be an early stage on a clinical continuum possibly leading to eclampsia. The premonitory signs and symptoms were then construed as diagnostic criteria for the poorly understood syndrome of preeclampsia, and this led to a perpetual debate that remains subject to wide disagreement and periodic updates. In this commentary, we will draw attention to the fact that the criteria for preeclampsia should be viewed from the prism of a screening test rather than as diagnostic of a condition in itself. Focusing research on developing better diagnostic and screening methods for what is clinically important, namely maternal and perinatal morbidity and mortality from hypertensive disorders of pregnancy, a long overdue upgrade from what was possible centuries ago, will ultimately lead to better management approaches to what really matters.
Asunto(s)
Preeclampsia/diagnóstico , Biomarcadores , Eclampsia/diagnóstico , Eclampsia/prevención & control , Femenino , Humanos , Hipertensión Inducida en el Embarazo/clasificación , Hipertensión Inducida en el Embarazo/diagnóstico , Tamizaje Masivo , Embarazo , ProteinuriaRESUMEN
INTRODUCCIÓN Y OBJETIVO: Los trastornos hipertensivos asociados al embarazo son considerados un problema de salud pública. Se busca describir las características clínicas y desenlaces materno-fetales de las pacientes con esta patología, atendidas en el Hospital Universitario de Santander (HUS) durante el primer semestre de 2017. MÉTODOS: Estudio observacional retrospectivo de corte transversal. Se incluyeron las pacientes en estado de embarazo o puerperio con diagnóstico o sospecha de trastorno hipertensivo; se excluyeron aquellas que no pudieron ser clasificadas o no correspondían a éstos. RESULTADOS: Se analizaron 181 historias clínicas; la edad de las pacientes osciló entre 14 y 44 años; el 43,7% eran primigestantes; el 40,3% tuvo un control prenatal inadecuado y el 27,5% tenía antecedente de trastorno hipertensivo en gestaciones previas. El 75,1% de las pacientes fueron clasificadas como preeclampsia, 18,2% con hipertensión gestacional, 4,4% con hipertensión más preeclampsia sobreagregada y 2,2% con hipertensión crónica. El 16,9% de las pacientes con preeclampsia debutaron antes de la semana 34, de las cuales el 91,3% tenían criterios de severidad; mientras que entre las demás, el 84% presentaron criterios de severidad. CONCLUSIONES: La preeclampsia fue el trastorno hipertensivo más frecuente, predominó la presentación tardía y severa con importantes tasas de complicación maternas y fetales. Mediante la implementación de estrategias de detección temprana y adecuada atención de los trastornos hipertensivos asociados al embarazo podrían mejorarse los desenlaces materno-fetales.
BACKGROUND AND OBJECTIVE: Hypertensive disorders of pregnancy are considered a public health issue. The aim is to describe the clinical features, maternal - fetal outcomes of patients with this disease, who were admitted at the University Hospital of Santander (Bucaramanga, Colombia) during the first half of 2017. METHOD: Cross-sectional retrospective observational study. Patients in pregnancy or puerperium with diagnosis of hypertensive disorder were included; those who could not be classified or did not correspond were excluded. RESULTS: 181 clinical charts were analyzed, the age of the patients ranged between 14 and 44 years, 43.7% were nulliparous, 40.3% had an inadequate prenatal control and 27.5% had history of hypertensive disorder in previous pregnancies. 75.1% were classified as preeclampsia, 18.2% as gestational hypertension, 4.4% as hypertension and superimposed preeclampsia and 2.2% with chronic hypertension; 16.9% of the patients were of an early-onset preeclampsia before week 34, of which 91.3% had criteria of severity; among the others, 84% presented criteria of severity. CONCLUSION: Preeclampsia was the most frequent hypertensive disorder, late and severe presentation prevailed with important maternal and fetal complication rates. Through the implementation of early detection strategies and adequate care of hypertensive disorders associated with pregnancy maternal and fetal outcomes could be improved.
Asunto(s)
Humanos , Femenino , Embarazo , Adolescente , Adulto , Adulto Joven , Hipertensión Inducida en el Embarazo/clasificación , Hipertensión Inducida en el Embarazo/diagnóstico , Hipertensión Inducida en el Embarazo/epidemiología , Preeclampsia/clasificación , Preeclampsia/diagnóstico , Preeclampsia/epidemiología , Resultado del Embarazo , Estudios Transversales , Estudios Retrospectivos , Síndrome HELLP/clasificación , Síndrome HELLP/diagnóstico , Síndrome HELLP/epidemiología , Colombia , Eclampsia/clasificación , Eclampsia/diagnóstico , Eclampsia/epidemiologíaRESUMEN
RESUMEN Los desórdenes hipertensivos del embarazo se encuentran dentro de las tres primeras causas de morbimortalidad materna y perinatal a nivel mundial, hasta el año 2016. Diferentes estudios realizados en los últimos 5 años e importantes organizaciones científicas han abordado este tema en el que existen discrepancias en cuanto a su etiopatogenia. Sin embargo, los avances logrados en la misma, la profundización en sus manifestaciones clínicas, los modos de presentación y los elementos diagnósticos han permitido el reconocimiento precoz y la efectividad del tratamiento. Esto ha ocasionado, principalmente en lo referente a los desórdenes hipertensivos tipo I, cambios que afectan desde la definición hasta el tratamiento. De esta manera, el presente documento pone al alcance de la comunidad médica una amplia revisión científica que facilita un mejor diagnóstico de la preeclampsia y de otras formas de hipertensión arterial en la etapa grávido-puerperal. Asimismo, contribuirá a reducir el error diagnóstico y logrará una intervención temprana para la obtención de mejores resultados maternos y perinatales (AU).
SUMMARY Hypertensive disorders of pregnancy are among the first three causes of maternal and perinatal Morbimortality in the world until 2016. Important scientific organizations and several studies carried out in the last five years have approached the theme, but there are still discrepancies with respect to etiopathogeny. Nevertheless, advances in it and deepening in its clinical manifestations, presentation ways and diagnostic elements have allowed its precocious recognition and diagnostic elements, causing changes from its definition up to its treatment, mainly in the case of the hypertensive disorders type I. In the current article, the authors put at reach of the medical community a wide scientific review facilitating a better diagnosis of preeclampsia and other forms of arterial hypertension in the pregnancy-puerperal stage that will contribute to reducing diagnosis error and making an early intervention, leading to better maternal and perinatal results (AU).
Asunto(s)
Humanos , Femenino , Embarazo , Preeclampsia , Hipertensión Inducida en el Embarazo/clasificación , Eclampsia , Hipertensión Inducida en el Embarazo/diagnóstico , Hipertensión Inducida en el Embarazo/etiología , Hipertensión Inducida en el Embarazo/patologíaAsunto(s)
Hipertensión Inducida en el Embarazo/fisiopatología , Preeclampsia/fisiopatología , Complicaciones Cardiovasculares del Embarazo/fisiopatología , Adulto , Aminoácido Oxidorreductasas/análisis , Aminoácido Oxidorreductasas/sangre , Recuento de Células Sanguíneas/métodos , Creatinina/análisis , Creatinina/sangre , Femenino , Humanos , Hipertensión Inducida en el Embarazo/clasificación , Embarazo , Proteinuria/orina , Ácido Úrico/análisis , Ácido Úrico/sangreRESUMEN
AIM: This study aimed to examine how the number of patients diagnosed with pre-eclampsia increased according to the Japanese classification of hypertensive disorders of pregnancy (HDP) that was revised in 2018. The effect of new classification on perinatal outcomes was also analyzed. METHODS: We enrolled 181 women with HDP who delivered at Hokkaido University Hospital between February 2011 and December 2017. All women were reclassified on the basis of the new classification, in which proteinuria was not required to diagnose pre-eclampsia in patients with maternal organ damage. The number and reasons of reclassification and the admission rate to the neonatal intensive care unit (NICU) and gestational age (GA) at the onset of HDP and at delivery were analyzed. RESULTS: In this cohort, 17 (9.4%) of 181 women with HDP were reclassified. Low platelet count (41.2%) and uteroplacental dysfunction (41.2%) were the two main causes for reclassification. GA at the onset of HDP (33.6 [29.9-36.1] weeks vs 37.4 [35.7-38.4] weeks; P < 0.001) and at delivery (35.9 [32.4-37.3] weeks vs 38.1 [37.3-39.6] weeks; P < 0.001) were significantly earlier in women with reclassification than women without reclassification. The NICU admission rate was higher in women with reclassification than women without reclassification (70.6% vs 20.4%; P < 0.001). CONCLUSION: Almost 10% of pregnant women were newly diagnosed with pre-eclampsia as per the new Japanese classification of HDP. Women with reclassification as pre-eclampsia had a greater risk of preterm delivery and NICU admission than those who were not reclassified.
Asunto(s)
Hipertensión Inducida en el Embarazo/clasificación , Hipertensión Inducida en el Embarazo/diagnóstico , Adulto , Estudios de Cohortes , Femenino , Edad Gestacional , Humanos , Recién Nacido , Cuidado Intensivo Neonatal/estadística & datos numéricos , Japón , Admisión del Paciente/estadística & datos numéricos , Preeclampsia/clasificación , Preeclampsia/diagnóstico , EmbarazoRESUMEN
Chronic hypertension in pregnancy is traditionally classified according to degree of blood pressure (BP) elevation. Alternatively, stratifying women as high or low risk based on the etiology of hypertension, baseline work-up, and comorbid medical conditions will better inform clinicians about thresholds to initiate antihypertensive therapy, target BPs, frequency of antepartum visits, and timing of delivery. Women classified as high-risk chronic hypertension as described here require stricter BP management and more frequent follow-up visits as their associated rates of adverse maternal and/or fetal/neonatal outcomes appear higher than women classified as low-risk chronic hypertension. The latter group can in most cases be managed similarly to the general obstetric population.
Asunto(s)
Antihipertensivos/uso terapéutico , Hipertensión/clasificación , Complicaciones Cardiovasculares del Embarazo/clasificación , Adulto , Aspirina/administración & dosificación , Enfermedad Crónica , Femenino , Humanos , Hipertensión/diagnóstico , Hipertensión/tratamiento farmacológico , Hipertensión Inducida en el Embarazo/clasificación , Hipertensión Inducida en el Embarazo/tratamiento farmacológico , Embarazo , Complicaciones Cardiovasculares del Embarazo/diagnóstico , Complicaciones Cardiovasculares del Embarazo/tratamiento farmacológico , Atención Prenatal/métodos , Factores de RiesgoRESUMEN
OBJECTIVE: Pregnancies affected by a hypertensive disorder (HDP) have increased uterine artery pulsatility index (UtA-PI) compared with that in healthy pregnancies. Women with HDP are also known to have lower cardiac output and increased systemic vascular resistance. The aim of this study was to investigate the relationship between central and uterine hemodynamics in HDP and uncomplicated pregnancy. METHODS: This was a prospective study of HDP and normotensive control singleton pregnancies presenting at a tertiary referral hospital between January 2012 and December 2017. Paired measurements of maternal hemodynamics, using a non-invasive device (USCOM-1A®), and UtA-PI were performed in the third trimester. HDP pregnancies were divided into preterm (onset < 37 weeks' gestation) and term (onset ≥ 37 weeks). Spearman's rank coefficient was used to assess the correlation between the central and uteroplacental hemodynamics. Regression analysis was performed to assess the association of UtA-PI with independent variables. RESULTS: We included 231 women with HDP (152 with preterm and 79 with term HDP) and 378 controls with normotensive pregnancy. Compared with controls, women with preterm HDP had significantly lower cardiac output (median (interquartile range (IQR)), 6.0 (5.1-7.2) vs 6.6 (5.8-7.5) L/min; P < 0.001) and significantly higher systemic vascular resistance (median (IQR), 1394 (1189-1670) vs 1063 (915-1222) dynes × s/cm5 ; P < 0.001) and UtA-PI (median (IQR), 1.0 (0.75-1.4) vs 0.67 (0.58-0.83); P < 0.001). Conversely, in women with term HDP, there were no significant differences in heart rate, cardiac output or UtA-PI compared with controls (all P > 0.05), while systemic vascular resistance was significantly higher (median (IQR), 1315 (1099-1527) vs 1063 (915-1222) dynes × s/cm5 ; P < 0.001). On multiple regression analysis, heart rate, mean arterial pressure and stroke volume were associated significantly with mean UtA-PI (all P < 0.001). CONCLUSIONS: Differences observed between HDP and normotensive pregnancies in third-trimester UtA resistance are mirrored in the central maternal hemodynamic parameters. Late pregnancy differences in the uteroplacental circulation in preterm and term HDP are an index of maternal cardiovascular function rather than being related to inadequate spiral artery remodeling and impaired placentation. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
Asunto(s)
Hemodinámica/fisiología , Hipertensión Inducida en el Embarazo/fisiopatología , Arteria Uterina/diagnóstico por imagen , Adulto , Presión Arterial , Gasto Cardíaco/fisiología , Femenino , Edad Gestacional , Frecuencia Cardíaca/fisiología , Humanos , Hipertensión Inducida en el Embarazo/clasificación , Circulación Placentaria/fisiología , Placentación/fisiología , Embarazo , Tercer Trimestre del Embarazo/fisiología , Estudios Prospectivos , Flujo Pulsátil/fisiología , Volumen Sistólico/fisiología , Ultrasonografía Doppler/métodos , Resistencia Vascular/fisiologíaAsunto(s)
Antihipertensivos/uso terapéutico , Monitoreo Ambulatorio de la Presión Arterial/métodos , Manejo de la Enfermedad , Hipertensión Inducida en el Embarazo , Femenino , Humanos , Hipertensión Inducida en el Embarazo/clasificación , Hipertensión Inducida en el Embarazo/diagnóstico , Hipertensión Inducida en el Embarazo/tratamiento farmacológico , EmbarazoRESUMEN
Hypertensive disorders of pregnancy include chronic hypertension, gestational hypertension, preeclampsia-eclampsia, and chronic hypertension with superimposed preeclampsia. These disorders are an important cause of maternal and fetal morbidity and mortality. Although advances in effective treatments have been made, current research has yet to identify a biochemical or diagnostic imaging marker to reliably predict preeclampsia. Despite current guidelines that address diagnosis and management of hypertensive disorders in pregnancy, health care providers may overlook or be unaware of signs that require immediate evaluation and treatment. This article reviews the definitions of hypertensive disorders of pregnancy, diagnosis, pathophysiology of preeclampsia, indications for treatment, neurologic sequelae, and counseling about the implications of hypertension in pregnancy for subsequent health.
Asunto(s)
Hipertensión Inducida en el Embarazo/diagnóstico , Hipertensión Inducida en el Embarazo/prevención & control , Bienestar Materno/estadística & datos numéricos , Guías de Práctica Clínica como Asunto , Atención Prenatal/organización & administración , Enfermedad Crónica , Femenino , Humanos , Hipertensión Inducida en el Embarazo/clasificación , Investigación Metodológica en Enfermería , Embarazo , Complicaciones Cardiovasculares del Embarazo/diagnóstico , Complicaciones Cardiovasculares del Embarazo/prevención & control , Factores de RiesgoAsunto(s)
Hipertensión Inducida en el Embarazo/diagnóstico , Hipertensión Inducida en el Embarazo/terapia , Hipertensión/diagnóstico , Hipertensión/terapia , Complicaciones Cardiovasculares del Embarazo/diagnóstico , Complicaciones Cardiovasculares del Embarazo/terapia , Femenino , Edad Gestacional , Síndrome HELLP , Humanos , Hipertensión Inducida en el Embarazo/clasificación , Atención Posnatal , Preeclampsia/diagnóstico , Preeclampsia/prevención & control , Preeclampsia/terapia , Embarazo , Atención Prenatal , ProteinuriaRESUMEN
Hypertensive disorders of pregnancy remain an unresolved and unpreventable problem in obstetrics. They remain one of the leading member of deadly triad causing maternal mortality, the other two being hemorrhage and sepsis which are preventable. The incidence of hypertensive disorders worldwide is 12 %. We have discussed various terminologies used to describe hypertension during pregnancy, risk factors, etiopathogenesis, pathophysiology, management guidelines, complications and long term consequences of hypertensive disorders of pregnancy in this chapter.
Asunto(s)
Presión Sanguínea , Hipertensión Inducida en el Embarazo/fisiopatología , Antihipertensivos/uso terapéutico , Presión Sanguínea/efectos de los fármacos , Femenino , Humanos , Hipertensión Inducida en el Embarazo/clasificación , Hipertensión Inducida en el Embarazo/mortalidad , Hipertensión Inducida en el Embarazo/terapia , Incidencia , Embarazo , Factores de Riesgo , Factores de Tiempo , Resultado del TratamientoRESUMEN
The American College of Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy was created to evaluate the existing literature, develop practice guidelines, and identify areas for future research focus. Several issues were identified that may not have been initially obvious during the process of developing this document, including limited practical use, a lack of high quality literature, conflicting recommendations, a potential for high resource utilization, need for continually updated information, and little headway in research that is clinically useful. The purpose of this review was to make suggestions to improving these guidelines' overall usefulness and consistency for the busy clinician.
Asunto(s)
Hipertensión Inducida en el Embarazo/terapia , Obstetricia , Guías de Práctica Clínica como Asunto , Femenino , Ginecología , Humanos , Hipertensión Inducida en el Embarazo/clasificación , Hipertensión Inducida en el Embarazo/prevención & control , Embarazo , Sociedades Médicas , Estados UnidosAsunto(s)
Humanos , Femenino , Embarazo , Complicaciones Cardiovasculares del Embarazo/clasificación , Complicaciones Cardiovasculares del Embarazo/tratamiento farmacológico , Hipertensión Inducida en el Embarazo/clasificación , Hipertensión Inducida en el Embarazo/tratamiento farmacológico , Hipertensión/clasificaciónRESUMEN
Hypertensive disorders of pregnancy are among the leading preventable contributors of maternal and fetal adverse outcomes, including maternal and fetal death. Blood pressure increase has a strong association with unfavorable pregnancy outcomes, including stroke and pulmonary edema. A persistent blood pressure measurement greater than or equal to 160/110 mm Hg lasting for more than 15 minutes, during pregnancy or postpartum, is considered an obstetric emergency and requires rapid appropriate treatment. Following evidence-based guidelines, implementing institutional polices, and understanding the classification and pathophysiology of hypertensive disorders of pregnancy are essential and can significantly improve the rate of preventable complications.
Asunto(s)
Manejo de la Enfermedad , Hipertensión Inducida en el Embarazo , Edema Pulmonar/prevención & control , Accidente Cerebrovascular/prevención & control , Determinación de la Presión Sanguínea , Diagnóstico Precoz , Intervención Médica Temprana/métodos , Femenino , Humanos , Hipertensión Inducida en el Embarazo/clasificación , Hipertensión Inducida en el Embarazo/diagnóstico , Hipertensión Inducida en el Embarazo/fisiopatología , Hipertensión Inducida en el Embarazo/terapia , Embarazo , Resultado del Embarazo , Edema Pulmonar/etiología , Accidente Cerebrovascular/etiologíaRESUMEN
BACKGROUND: The Finnish Pre-eclampsia Consortium (FINNPEC) case-control cohort consisting of 1447 pre-eclamptic and 1068 non-pre-eclamptic women was recruited during 2008-2011 to study genetic background of pre-eclampsia and foetal growth. Pre-eclampsia was defined by hypertension and proteinuria according to the American College of Obstetricians and Gynecologists (ACOG) 2002 classification. The ACOG Task Force Report on Hypertension in Pregnancy (2013) and The International Society for the Study of Hypertension in Pregnancy (ISSHP) (2014) have published new classifications, in which proteinuria is not necessary for diagnosis when specific symptoms are present. For diagnoses based on proteinuria, the ISSHP 2014 criteria raised its threshold to 2+ on dipstick. We studied how the new classifications would affect pre-eclampsia diagnoses in the FINNPEC cohort. METHODS: We re-evaluated pre-eclampsia diagnosis using the ACOG 2013 and the ISSHP 2014 classifications in pre-eclamptic women whose proteinuria did not exceed 1+ on dipstick (n = 68), in women with gestational hypertension (n = 138) and in women with chronic hypertension (n = 66). RESULTS: The number of women with pre-eclampsia increased 0.8 % (1459/1447) according to the ACOG 2013 criteria and 0.6 % (1455/1447) according to the ISSHP 2014 criteria. All 68 women with the amount of proteinuria not exceeding 1+ on dipstick diagnosed originally pre-eclamptic met the ACOG 2013 criteria but only 20 women (29.4 %) met the ISSHP 2014 criteria. Seven (5.1 %) and 35 (25.4 %) women with gestational hypertension were diagnosed with pre-eclampsia according to the ACOG 2013 and the ISSHP 2014 criteria, respectively. Correspondingly five (7.6 %) and 21 (31.8 %) women with chronic hypertension were diagnosed with pre-eclampsia according to the ACOG 2 013 and the ISSHP 2014 criteria. CONCLUSIONS: Only minor changes were observed in the total number of pre-eclamptic women in the FINNPEC cohort when comparing the ACOC 2002 classification with the ACOG 2013 and ISSHP 2014 classifications.
Asunto(s)
Hipertensión Inducida en el Embarazo/clasificación , Preeclampsia/diagnóstico , Proteinuria/clasificación , Evaluación de Síntomas/clasificación , Adulto , Comités Consultivos , Estudios de Casos y Controles , Estudios de Cohortes , Femenino , Finlandia , Humanos , Preeclampsia/clasificación , Embarazo , Valores de Referencia , Evaluación de Síntomas/métodosRESUMEN
Hypertensive disorders complicate 5%-10% of pregnancies with increasing incidence mainly due to upward trends in obesity globally. In the last century, several terminologies have been introduced to describe the spectrum of this disease. The current and widely used classification of hypertensive pregnancy disorders was introduced in 1972 and in 1982, but has not been free of controversy and confusion. Unlike other diseases, the existing terminology combines signs and symptoms, but does not describe the underlying pathology of the disease itself. In this commentary, a detailed account is given to vascular disorder of pregnancy (VDP) as an inclusive terminology taking into account the underlying pathology of the disease on affected organs and systems. A simple and uniform classification scheme for VDP is proposed.
Asunto(s)
Eclampsia/clasificación , Síndrome HELLP/clasificación , Hipertensión Inducida en el Embarazo/clasificación , Preeclampsia/clasificación , Complicaciones del Embarazo/clasificación , Terminología como Asunto , Enfermedades Vasculares/clasificación , Femenino , Humanos , EmbarazoAsunto(s)
Antihipertensivos/uso terapéutico , Lactancia Materna , Citocinas/metabolismo , Hipertensión Inducida en el Embarazo/tratamiento farmacológico , Preeclampsia/tratamiento farmacológico , Antihipertensivos/administración & dosificación , Femenino , Humanos , Hipertensión Inducida en el Embarazo/clasificación , Hipertensión Inducida en el Embarazo/metabolismo , EmbarazoRESUMEN
Hypertensive disorders are the most common medical complication of pregnancy. As such, a large part of antenatal care is dedicated to the detection of pre-eclampsia, the most dangerous of the hypertensive disorders. The highlights of this chapter include progress in the use of out-of-office blood pressure measurement as an adjunct to office blood pressure measurement, pre-eclampsia defined as proteinuria or relevant end-organ dysfunction, antihypertensive therapy for severe and non-severe hypertension and post-partum follow-up to mitigate the increased cardiovascular risk associated with any of the hypertensive disorders of pregnancy.